CKD Bio Corp
KRX:063160
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CKD Bio Corp
Net Income
CKD Bio Corp
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CKD Bio Corp
KRX:063160
|
Net Income
-₩2.9B
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Net Income
₩185.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income
₩253.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income
₩187.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
61%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income
₩12B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-4%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Net Income
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
CKD Bio Corp
Glance View
CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-12-11. The firm mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. The company also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The firm distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.
See Also
What is CKD Bio Corp's Net Income?
Net Income
-2.9B
KRW
Based on the financial report for Dec 31, 2025, CKD Bio Corp's Net Income amounts to -2.9B KRW.
What is CKD Bio Corp's Net Income growth rate?
Net Income CAGR 3Y
44%
The average annual Net Income growth rates for CKD Bio Corp have been 44% over the past three years .
